OTHER FUNCTIONS TOPIC 267, MULTIFUNCTIONAL THERAPEUTICS USING ENGINEERED PLANT V

其他功能主题 267，使用工程植物 V 进行多功能治疗

• 批准号: 8564269
• 负责人: BRUCE OBERHARDT
• 金额: $ 120万
• 依托单位: NANOVECTOR, INC.
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-09-28 至 2014-09-27
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8564269
• 关键词: Animal Model; Animals; Antineoplastic Agents; Biodistribution; Biological Markers; Bypass; Cell Nucleus; Cells; Cellular Structures; Data; Disease; Engineering; Environment; Food Chain; Human; Medical Imaging; Mus; Organ; Pharmaceutical Preparations; Pharmacology; Phase; Plant Viruses; Plants; Process; Production; System; Techniques; Therapeutic; Therapeutic Uses; Toxic effect; Virus; Xenograft procedure; base; biomaterial compatibility; cancer cell; drug efficacy; immunogenicity; implantable device; in vivo; manufacturing scale-up; melanoma; nanodevice; nanoparticle; nanovector; pre-clinical; sensor

A ¿biologic nanoparticle¿ is the basis of this proposal. The plant virus nanoparticle (PVN) is based on a virus that: exists in the human food chain; is nontoxic and of low immunogenicity; can load medical imaging agents and/or therapeutic drugs into its ¿cargo chamber¿ by a simple process; and can be engineered to identify and enter cancer cells and release drug payloads inside cell structures, such as the nucleus where most anticancer drugs operate, bypassing most cancer cell defenses. It has a highly evolved sensor/actuator system to release cargo only in the targeted cell. In this Phase II project, NanoVector, Inc. will: perform mouse pharmacology studies and efficacy studies using human melanoma xenografts; increase PVN production efficiency and scalability; perform long term toxicity studies with biodistribution and bioelimination data, as well as early IND enabling studies, and initiation of large animal studies.

生物纳米颗粒是这一提议的基础。植物病毒纳米粒(PVN)基于一种病毒，这种病毒存在于人类食物链中，无毒，免疫原性低，可以通过简单的过程将医学显像剂和/或治疗药物装载到其货舱中，并且可以被设计成识别和进入癌细胞，并在细胞结构内释放药物有效载荷，例如大多数抗癌药物作用的细胞核，绕过大多数癌细胞防御。它有一个高度进化的传感器/执行器系统，只在目标细胞中释放货物。在这一第二阶段项目中，Nanovector公司将：使用人类黑色素瘤异种移植进行小鼠药理研究和疗效研究；提高PVN的生产效率和可扩展性；利用生物分布和生物消除数据进行长期毒性研究，以及早期IND使能研究，并启动大型动物研究。